EA201000219A1 - Способ и композиция для лечения в-клеточных пролиферативных нарушений - Google Patents

Способ и композиция для лечения в-клеточных пролиферативных нарушений

Info

Publication number
EA201000219A1
EA201000219A1 EA201000219A EA201000219A EA201000219A1 EA 201000219 A1 EA201000219 A1 EA 201000219A1 EA 201000219 A EA201000219 A EA 201000219A EA 201000219 A EA201000219 A EA 201000219A EA 201000219 A1 EA201000219 A1 EA 201000219A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disturbances
treatment
composition
cellular proliferative
methods
Prior art date
Application number
EA201000219A
Other languages
English (en)
Inventor
Ричард Риклз
Маргарет С. Ли
Original Assignee
Комбинейторкс, Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Комбинейторкс, Инкорпорейтед filed Critical Комбинейторкс, Инкорпорейтед
Publication of EA201000219A1 publication Critical patent/EA201000219A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение предусматривает композиции и способы для лечения В-клеточного пролиферативного нарушения, которые используют агонист рецептора А2А и один или более ингибиторов PDE. Способы и композиции могут также предусматривать применение антипролиферативного соединения.
EA201000219A 2007-07-17 2008-07-17 Способ и композиция для лечения в-клеточных пролиферативных нарушений EA201000219A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95030707P 2007-07-17 2007-07-17
US96558707P 2007-08-21 2007-08-21
PCT/US2008/008758 WO2009011893A2 (en) 2007-07-17 2008-07-17 Treatments of b-cell proliferative disorders

Publications (1)

Publication Number Publication Date
EA201000219A1 true EA201000219A1 (ru) 2010-12-30

Family

ID=40260271

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000219A EA201000219A1 (ru) 2007-07-17 2008-07-17 Способ и композиция для лечения в-клеточных пролиферативных нарушений

Country Status (8)

Country Link
US (1) US20090053168A1 (ru)
EP (1) EP2178369A4 (ru)
AU (1) AU2008276451A1 (ru)
BR (1) BRPI0813516A2 (ru)
CA (1) CA2694983A1 (ru)
EA (1) EA201000219A1 (ru)
TW (1) TW200920381A (ru)
WO (1) WO2009011893A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20100003193A1 (en) 2008-07-03 2010-01-07 University Of Virginia Patent Foundation Unit dosage of apadenoson
DK2321012T3 (en) 2008-08-20 2018-12-03 Solasia Pharma K K ORGANIC RELATIONS AND PROCEDURES FOR TREATING CANCER
CN107964016B (zh) 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
AR082601A1 (es) * 2010-08-09 2012-12-19 Verona Pharma Plc Formas cristalinas de compuestos de pirimido[6,1-a]isoquinolin-4-ona
EP2611437B1 (en) * 2010-09-02 2017-03-29 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2014142220A1 (ja) * 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US9314460B1 (en) * 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
EP4274612A1 (en) * 2021-01-07 2023-11-15 The Regents of the University of California Modulation of cd46 cell surface marker in both androgen receptor-positive and negative cancer cells
WO2022150517A1 (en) * 2021-01-07 2022-07-14 The Regents Of The University Of California Modulation of cd46 cell surface expression and therapeutic use thereof
CN112939996B (zh) * 2021-02-01 2022-04-26 湖南文理学院 一种以n-氧化吡啶衍生物为识别基团的近红外荧光探针化合物及其制备和应用
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5925682A (en) * 1995-11-20 1999-07-20 Immunotech Inc. Epinephrine as inhibitor of cancerous tumors
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US20030017150A1 (en) * 2001-03-14 2003-01-23 Torphy Theodore J. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
WO2003029264A2 (en) * 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2512819A1 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
PT1641764E (pt) * 2003-06-26 2011-10-27 Novartis Ag Inibidores de p38 quinase a base de heterociclo de 5 elementos
ES2315703T3 (es) * 2003-07-25 2009-04-01 Novartis Ag Inhibidores de la quinasa p-38.
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US7939057B2 (en) * 2006-01-25 2011-05-10 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
EP2178369A4 (en) 2010-12-15
CA2694983A1 (en) 2009-01-22
WO2009011893A2 (en) 2009-01-22
WO2009011893A3 (en) 2009-03-19
TW200920381A (en) 2009-05-16
US20090053168A1 (en) 2009-02-26
AU2008276451A1 (en) 2009-01-22
BRPI0813516A2 (pt) 2014-12-30
EP2178369A2 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
EA201000219A1 (ru) Способ и композиция для лечения в-клеточных пролиферативных нарушений
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
ECSP17020133A (es) Derivados de benzodiazepina citotóxicos
WO2010138820A3 (en) N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
NZ744516A (en) Selective estrogen receptor degraders and uses thereof
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200801118A1 (ru) Способ ингибирования flt3 киназы
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
EA200801430A1 (ru) Производные триазола
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).